Astrazeneca

FromAstraZeneca ([email protected])
Subject (44)Enhertu approved in US for HER2-mutant NSCLC
Preheader (148)Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
Typography
Arial
Colors
Text Analysis
Body Words234
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px788 px
X-Spam Score0.4
Preheader OptimizedNo
Timing
Day of WeekTuesday
TimeEvening

Enhertu approved in US for HER2-mutant NSCLC

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
Enhertu approved in US for HER2-mutant NSCLC